TTOO Current Deferred Revenue from 2010 to 2025

TTOO Stock  USD 0.22  0.01  4.35%   
T2 Biosystms Current Deferred Revenue yearly trend continues to be very stable with very little volatility. Current Deferred Revenue is likely to drop to about 191.5 K. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2014-12-31
Previous Quarter
237 K
Current Value
233 K
Quarterly Volatility
749.2 K
 
Yuan Drop
 
Covid
Check T2 Biosystms financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among T2 Biosystms' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 4.9 M or Total Revenue of 9.8 M, as well as many indicators such as Price To Sales Ratio of 2.49, Dividend Yield of 0.0 or Days Sales Outstanding of 131. TTOO financial statements analysis is a perfect complement when working with T2 Biosystms Valuation or Volatility modules.
  
Check out the analysis of T2 Biosystms Correlation against competitors.
To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.

Latest T2 Biosystms' Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of T2 Biosystms over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. T2 Biosystms' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in T2 Biosystms' overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Very volatile
   Current Deferred Revenue   
       Timeline  

TTOO Current Deferred Revenue Regression Statistics

Arithmetic Mean577,882
Geometric Mean274,692
Coefficient Of Variation136.48
Mean Deviation589,059
Median224,000
Standard Deviation788,721
Sample Variance622.1B
Range2.4M
R-Value(0.07)
Mean Square Error662.8B
R-Squared0.01
Significance0.78
Slope(12,305)
Total Sum of Squares9.3T

TTOO Current Deferred Revenue History

2025191.5 K
2024201.6 K
2023224 K
2022172 K
2021518 K
2020230 K
2019285 K

About T2 Biosystms Financial Statements

T2 Biosystms investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how TTOO Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue201.6 K191.5 K
When determining whether T2 Biosystms offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of T2 Biosystms' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of T2 Biosystms Stock. Outlined below are crucial reports that will aid in making a well-informed decision on T2 Biosystms Stock:
Check out the analysis of T2 Biosystms Correlation against competitors.
To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.03)
Revenue Per Share
0.999
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.90)
Return On Equity
(6.22)
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.